How will Pfizer and Moderna protect their vaccine patent applications?
While regulatory exclusivity will effectively protect Covid vaccines for at least a decade in Europe and the U.S, they will be unprotected by regulatory exclusivity in Israel.
Since the drugs have not been approved, it is difficult to determine which patents/patent applications protect the Pfizer/BioNTech and Moderna vaccines at this time. After the approval of both vaccines by the FDA, the patent linkage system in the U.S will disclose the relevant patents.
Moderna has published a list of seven U.S patents it claims protect its vaccine (US 10,703,789, US 10,702,600, US 10,577,403, US 10,442,756, US 10,266,485, US 10,064,959, US 9,868,692). While Moderna has filed patent applications worldwide that correspond to the U.S patents, they do not appear to have filed Israeli patent applications that correspond to these U.S patents. However, Moderna has filed recent patent applications in Israel, and one of those applications may protect its vaccine. Both Pfizer and BioNTech have also filed recent patent applications in Israel, which may protect their Covid-19 vaccine.Significantly, Moderna has committed to waiving enforcement of its patents until after the end of the Covid-19 crisis. As of now, Pfizer has not made a similar pledge. However, despite the lack of a commitment, the backlash from using a patent to force a generic competitor to stop producing a generic Covid-19 vaccine will likely deter Pfizer from enforcing its Covid-19 vaccine patents until after the crisis is over. Further, any enforcement action to prevent generics from entering the market also risks the issuance of compulsory licenses by governments in different countries. The impact of a compulsory license can have wide-ranging effects. For example, the public relations impact of Israel's compulsory license for Abbvie's Kaletra at the start of the Covid crisis led Abbvie to waive enforcement of its Kaletra patents worldwide. In particular, Moderna may be exposed to U.S government action, as it appears to have received U.S government funding for several of its relevant patents. Such funding would allow the U.S Government to use "March In Rights" to grant licenses to Moderna's vaccine. In addition, Market/Data Exclusivity will also allow Pfizer and Moderna to protect their vaccine from competitors: Both the Moderna and Pfizer vaccines are mRNA based. This means that from a regulatory standpoint, they are considered biological agents. In major jurisdictions, new medicinal agents approved by regulatory agencies (e.g. U.S FDA, European Medicines Agency, Israeli Ministry of Health) receive varying periods of market or data exclusivity, a type of protection different than patents. Market exclusivity means that while generics can get their formulation approved, regulatory agencies will not grant a marketing authorization allowing the company to sell its formulation. Data exclusivity goes further and prevents generics from relying on the data provided to the regulatory agency by the innovator, thereby effectively blocking the generic from even registering its drug. Biological agents are protected by market/data exclusivity for 12 years in the U.S and 10-11 years in Europe. In contrast, with the U.S, Europe, and other major jurisdictions, Israel does not offer any market/data exclusivity for biological agents. This means that while regulatory exclusivity will effectively protect Covid-19 vaccines for at least a decade in Europe and the U.S, they will be unprotected by regulatory exclusivity in Israel.
Although there has been discussion about extending the market exclusivity granted to chemical agent drugs to biological drugs in Israel, this has yet to occur. Finally, while there is no regulatory exclusivity for biological agents in Israel, the Israeli Ministry of Health will not approve a generic agent unless it is first approved by either the FDA, European Medicines Authority (EMA), Switzerland, Japan, Canada, Australia, or New Zealand. Therefore, presently if a generic vaccine cannot be approved in one of the countries mentioned above, it would not be approved in Israel.
Adv. Ephraim Heiliczer is a Senior Associate in the Intellectual Property and Regulatory Compliance Group at Pearl Cohen law firm